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The poor performance of several recent clinical trials targeting elevation of high-density lipoprotein (HDL) 
cholesterol1–3 and the recent Mendelian genetic studies ques-
tioning a causal link between genetic variants controlling HDL 
cholesterol levels and cardiovascular disease risk4 argue for a 
reappraisal of our understanding of HDL. Such a reappraisal 
demands that we question assumptions about the pathobiol-
ogy of the lipoprotein, particularly in cases in which direct 
investigation is lacking. Much of what is known biologically 
about apolipoprotein A1 (apoA1) in human studies comes 
from investigations using isolated lipoprotein particles from 
the circulation (plasma or serum) with the use of buoyant den-
sity ultracentrifugation. As a known exchangeable lipoprotein, 
it is widely recognized that the vast majority of apoA1 within 
the circulation resides on spherical HDL particles, where it 
serves as the major structural protein of a complex macromo-
lecular assembly of lipoprotein particles with defined buoyant 
density (1.063≤d≤ 1.21).5 An unproven assumption is that the 
numerous biological functions observed with HDL or apoA1 
recovered from the circulation will mirror what occurs else-
where in vivo.
Clinical Perspective on p 1655
The functional properties of apoA1 and HDL within the 
circulation, however, may not faithfully reflect what occurs 
within the artery wall. Early studies identified that lipopro-
teins isolated from the artery wall, particularly low-density 
lipoprotein (LDL), undergo assorted alterations including 
proteolysis, various oxidative modifications, and lipolysis to 
varying extents.6,7 Several years ago, we reported that apoA1 
Background—Prior studies show that apolipoprotein A1 (apoA1) recovered from human atherosclerotic lesions is highly 
oxidized. Ex vivo oxidation of apoA1 or high-density lipoprotein (HDL) cross-links apoA1 and impairs lipid binding, 
cholesterol efflux, and lecithin-cholesterol acyltransferase activities of the lipoprotein. Remarkably, no studies to date 
directly quantify either the function or HDL particle distribution of apoA1 recovered from the human artery wall.
Methods and Results—A monoclonal antibody (10G1.5) was developed that equally recognizes lipid-free and HDL-
associated apoA1 in both native and oxidized forms. Examination of homogenates of atherosclerotic plaque–laden 
aorta showed >100-fold enrichment of apoA1 compared with normal aorta (P<0.001). Surprisingly, buoyant density 
fractionation revealed that only a minority (<3% of total) of apoA1 recovered from either lesions or normal aorta resides 
within an HDL-like particle (1.063≤d≤1.21). In contrast, the majority (>90%) of apoA1 within aortic tissue (normal and 
lesions) was recovered within the lipoprotein-depleted fraction (d>1.21). Moreover, both lesion and normal artery wall 
apoA1 are highly cross-linked (50% to 70% of total), and functional characterization of apoA1 quantitatively recovered 
from aorta with the use of monoclonal antibody 10G1.5 showed ≈80% lower cholesterol efflux activity and ≈90% lower 
lecithin-cholesterol acyltransferase activity relative to circulating apoA1.
Conclusions—The function and distribution of apoA1 in human aorta are quite distinct from those found in plasma. The 
lipoprotein is markedly enriched within atherosclerotic plaque, predominantly lipid-poor, not associated with HDL, 
extensively oxidatively cross-linked, and functionally impaired. 
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recovered from human atherosclerotic arterial lesions was 
selectively targeted for oxidative modification by myeloper-
oxidase-generated and NO-derived oxidants and that oxida-
tive modification of apoA1 and HDL ex vivo to a comparable 
extent resulted in loss of cholesterol efflux activity of the 
lipoprotein.8 Parallel functional characterization and mass 
spectrometry studies of circulating HDL isolated by buoyant 
density ultracentrifugation revealed that higher apoA1 con-
tent of oxidative modifications specifically formed by myelo-
peroxidase- and NO-derived oxidants was associated with 
impairment in plasma membrane transporter ATP-binding cas-
sette A1 (ABCA1)–dependent cholesterol efflux function of 
the lipoprotein,8 lecithin-cholesteryl acyltransferase (LCAT) 
activity, and acquisition of proinflammatory activity.9,10 
Similar findings have been replicated by other groups,11,12 and 
numerous additional proteomics studies have since mapped 
site-specific oxidative modifications to apoA1 recovered from 
the human artery wall.13–16 These studies collectively reveal 
that apoA1 is extensively oxidatively modified within an 
atherosclerotic-laden artery wall, and similar oxidative modi-
fications to the lipoprotein ex vivo are associated with proath-
erogenic changes in apoA1 function. However, no studies to 
date have directly examined the functional properties or the 
particle distribution of apoA1 recovered from human artery 
wall. The paucity of direct functional characterization stud-
ies is likely a result of the significant challenges that exist in 
obtaining sufficient quantities of fresh human arterial tissue 
for such biochemical and biological studies.
Herein we sought to examine both the distribution and the 
functional properties of apoA1 recovered from the human 
artery wall. The present studies demonstrate multiple remark-
able findings, including direct evidence that the biological 
function and HDL particle distribution of apoA1 within both 
normal and atherosclerosis-laden human aortic tissues are 
markedly distinct from those of circulating apoA1 and HDL. 
These studies suggest that the historical focus thus far on cir-
culating HDL cholesterol levels may not adequately reflect the 
actual situation with regard to apoA1 function and HDL par-
ticle distribution within the artery wall.
Materials and Methods
Materials
D2O was purchased from Cambridge Isotopes, Inc (Andover, MA). 
Chelex-100 resin, fatty acid–free bovine serum albumin, and crys-
talline catalase (from bovine liver; thymol-free) were purchased 
from Boehringer-Mannheim (Ridgefield, CT). Sodium phosphate, 
H2O2, and NaOCl were purchased from Fisher Chemical Company (Pittsburgh, PA). Commercial apoA1 antibodies were from Abcam 
(Cambridge, MA), Santa Cruz Biotechnologies (South San Francisco, 
CA), and Genway/Sigma (St Louis, MO). 1,2-Dimyristoyl-sn-
glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-
4-yl) (NBD-PE) was purchased from Avanti Polar Lipids. All other 
materials were purchased from Sigma Chemical Company (St Louis, 
MO) except where indicated.
Methods
General Procedures
Circulating HDL and plasma-derived apoA1 (purified) were obtained 
from healthy volunteer donors who gave written informed consent, 
and the institutional review board of the Cleveland Clinic approved 
the study protocol. Mouse studies involving monoclonal antibody 
(mAb) generation were performed under protocols approved by the 
Institutional Animal Care and Use Committee at the Cleveland Clinic. 
Lipoproteins, including HDL and HDL-like particles (1.063≤d≤1.21) 
from plasma and tissue homogenates, respectively, were isolated by 
sequential buoyant density ultracentrifugation at low salt concentra-
tions with the use of D2O/sucrose.17 Protein concentrations were deter-
mined by Markwell modified protein assay with bovine serum albumin 
as standard. Human apoA1 used as control for cholesterol efflux and 
LCAT activity assays was purified as described.18 Reconstituted HDL 
(rHDL) from isolated apoA1 was prepared by the cholate dialysis 
method19 with the use of a molar ratio of apoA1:1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphocholine:cholesterol of 1:100:10. HDL particles 
were further purified by gel filtration chromatography with the use of a 
Sephacryl S300 column (GE Healthcare,Waukesha, WI) on a Bio-Rad 
Biologics DuoFlo FPLC (Bio-Rad, Hercules, CA). Myeloperoxidase 
(donor: hydrogen peroxide, oxidoreductase, EC 1.11.1.7) was isolated 
(final A430/A280 ratio of 0.6) as described,8,13,14 and its concentration was 
determined spectrophotometrically (ε430=170 mmol/L−1 cm−1).8,13,14 
H2O2 concentrations20 and ─OCl concentrations8,13,14 were each deter-
mined spectrophotometrically (ε240=39.4 mol/L−1·cm−1 and ε292=350 
mol/L−1·cm−1, respectively) before use. Peroxynitrite (ONOO−) was 
purchased from Cayman Chemicals (Ann Arbor, MI) and quantified 
spectrophotometrically before use (ε302=1.36 mmol/L−1·cm−1).13,14 All 
buffers used were passed through a Chelex-100 column and supple-
mented with 100 μmol/L diethylenetriaminepentaacetic acid (DTPA) 
to remove any trace levels of redox-active metals. All glassware used 
was rinsed with 100 μmol/L DTPA, pH 7.4, and then Chelex-100–
treated distilled deionized H2O and baked at 500°C before use. SDS-
PAGE was performed as described.13
Tissue Collection
Fresh surgical specimens of human aortic tissue were obtained as dis-
carded material both at time of organ harvest from transplant donors 
and during valve/aortic arch (“elephant trunk”) replacement surgery. 
Tissue was immediately rinsed in ice-cold normal saline until free of 
visible blood, submerged in argon-sparged 65 mmol/L sodium phos-
phate buffer (pH 7.4) supplemented with 100 μmol/L DTPA and 100 
μmol/L butylated hydroxytoluene, and stored at −80°C in screw-cap 
specimen containers in which head space was purged with argon. 
Butylated hydroxytoluene was omitted from buffer in specimens in 
which apoA1 was isolated for functional activity assays.
mAb 10G1.5 Generation, Specificity, and Labeling
Hybridoma cell lines were generated by immunizing apoA1−/− mice 
with purified delipidated human apoA1 isolated from HDL recov-
ered from healthy donors. Among the positive clones, subclones were 
screened until a mAb with desired binding specificity for equal rec-
ognition of all forms of apoA1 (see below) was identified. The sub-
clone, mAb 10G1.5, was selected by screening for equal recognition 
of lipid-free and lipidated (in rHDL) apoA1 under native conditions, 
as well as after oxidation by exposure to multiple different systems 
including myeloperoxidase/H2O2/Cl−, myeloperoxidase/H2O2/NO2−, 
and CuSO4 (oxidized as outlined below). To produce sufficient lev-
els of 10G1.5 for immunoaffinity purification of apoA1 from arte-
rial tissues, hybridoma clones were injected into pristane-treated 
male BALB/c mice (8 weeks of age). Ascites fluid was collected, 
precipitated with ammonium sulfate, then bound and eluted from 
a protein A/G column (Thermo Scientific Pierce, Rockford, IL) to 
purify mouse mAbs. Isotypes of the mAbs were determined with the 
mouse mAb isotyping kit (catalog No. 26179, Pierce Rapid Antibody 
Isotyping Strips plus Kappa and Lambda–Mouse, Thermo Scientific 
Pierce, Rockford, IL).
Specificity of mAb 10G1.5 was tested with the use of apoA1 or 
rHDL either in native form or after incubation at 37°C in 60 mmol/L 
Na[PO4] buffer (pH 7.4) with multiple different oxidation systems. The 
different myeloperoxidase systems consisted of 19 nmol/L myeloper-
oxidase, 100 µmol/L DTPA, 40 µmol/L H2O2, and either 100 mmol/L 
NaCl or 1 mmol/L KBr or 1 mmol/L NaNO2 as indicated. Horseradish 
peroxidase (19 nmol/L) was used with 40 µmol/L H2O2. ApoA1 and 
rHDL were exposed to myeloperoxidase and horseradish peroxidase 
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for 90 minutes at 37°C, and the reactions were stopped by addition 
of 2 mmol/L methionine and 300 nmol/L catalase. All other oxidation 
reactions were performed for 24 hours at 37°C. Final concentrations of 
oxidants used were as follows: H2O2, 40 µmol/L; ONOO−, 40 µmol/L; 
ONOO−/HCO3−, 40 µmol/L each; CuSO4, 10 µmol/L; CuSO4/H2O2, 10 
and 40 µmol/L, respectively; FeCl3, 10 µmol/L; and FeCl3/H2O2, 10 
and 40 µmol/L, respectively. ApoA1 or rHDL (prepared from apoA1 or 
their various oxidized versions) was coated at 0.5 µg/mL into enzyme 
immunoassay plates and probed with 10 ng/mL anti-total apoA1 mAb 
10G1.5 at room temperature for 1 hour. For Western blot analyses, 
mAb 10G1.5 was IRDye labeled (LI-COR Biosciences, Lincoln NE) 
with the use of the LI-COR IRDye 800CW high-molecular kit at a 
dye/protein ratio at 4:1 and visualized by infrared imaging. The IRDye 
800CW dye bears an N-hydroxysuccinimide ester reactive group that 
couples to free amino groups on the antibody, forming a stable conju-
gate with antibody. Coupling was performed according to the manufac-
turer’s instructions.
Human ApoA1 Quantification
Human apoA1was quantified by a Food and Drug Administration–
approved apoA1 immunoassay on the Abbott ARCHITECT ci8200 
Integrated Analyzer System (Abbott Labs, Abbott Park, IL). All other 
apoA1 was quantified by quantitative immunoblot analysis with the 
use of mAb 10G1.5 as the detecting antibody, as determined against 
a standard curve of known purified apoA1 standard. Immunoreactive 
bands were quantified with the use of Image Studio software (ver-
sion 2, LI-COR) or Image J (version 1.46; http://rsbweb.nih.gov/). All 
nascent HDL particles, as well as isolated human HDL2 and HDL3, 
were further purified by gel filtration chromatography with the use of 
a Sephacryl S300 column (GE Healthcare, Waukesha, WI) on a Bio-
Rad Biologics DuoFlo FPLC.
Aortic Tissue Homogenization 
Atherosclerotic lesions from aortic tissues were from subjects (n>20) 
with an average age of 83±3 years. Normal human aortic tissues were 
obtained from transplant donors (n=5) from the Cleveland Clinic and 
had an average age of 23±7 years. All tissue homogenization and lipo-
protein fractionation procedures were performed within a cold room 
to ensure maintaining tissue and sample temperatures <4°C. Frozen 
tissue blocks (submerged in 65 mmol/L sodium phosphate buffer, 
pH 7.4, under argon, within screw-cap containers) were thawed by 
placement of the containers in an ice/water bath. Immediately before 
complete thaw, ice-cold Ca2+- and Mg2+-free Chelex-100–treated 
PBS supplemented with 100 μmol/L DTPA, pH 7.4, was added to 
rinse the tissue 5 times to remove any residual blood from tissue. 
The aorta segment was cleaned of adventitial fat and again rinsed 
3 times with ice-cold PBS supplemented with 100 µmol/L DTPA. 
Wet weigh of the aorta was determined, and the tissue was cut into 
small pieces and then suspended in ice-cold Ca2+- and Mg2+-free PBS 
supplemented with both 100 μmol/L DTPA (pH 7.4) and a protease 
inhibitor cocktail (Sigma-Aldrich, catalog No. P8340), which was 
included in all subsequent solutions used for homogenation and lipo-
protein isolation. Aortic tissues were homogenized in an ice/water 
bath with a motor-driven Brinkmann homogenizer for 30-second 
intervals 5 times with 2 minutes of rest between homogenizations. 
Care was taken throughout homogenization to maintain a temperature 
at or close to 0°C by keeping the homogenization vessel submerged 
within slush (ice/water bath). The crude homogenate was centri-
fuged at low speed of 15 000g for 30 minutes at 0°C, and the pel-
let was discarded. This low-speed supernatant (lesion homogenate) 
was then used for buoyant density isolation of LDL/very-low-density 
lipoprotein (VLDL) (d<1.063), HDL (1.063≤d≤1.21), and lipopro-
tein-depleted (LPD) fractions (d>1.21). Fractions were dialyzed at 
4°C 4 times against 4 L of 5 mmol/L ammonium bicarbonate, with 
50 µmol/L DTPA (pH 7.4) and 25 µmol/L butylated hydroxytoluene 
changed every 4 hours. A last change of buffer was against 4 L of ice-
cold Chelex-100–treated 1× PBS, pH 7.4.
Immunoaffinity Isolation of ApoA1 From Aortic  
Tissue Homogenate
Immunoaffinity resin was generated by covalently coupling mAb 
10G1.5 to AminoLink Plus (Pierce Chemical, Rockford, IL) resin at 
a density of 1.5 mg antibody per milliliter of resin in an amine-free 
buffer (PBS, pH 7.4) according to the manufacturer’s instruction. 
Reactive non–antibody-bound sites on the resin were blocked with 
the addition of excess ethanolamine. The affinity gel was drained, 
and antibody concentration in the flow-through was determined to 
calculate cross-linking efficiency, which was >90%. The gel was 
then rinsed extensively with 1 mol/L TRIS, pH 7.4, and 1 mol/L 
NaCl and then equilibrated in 1× PBS, pH 7.4, before use or storage 
(0.002% sodium azide was added if stored). Individual 1-time use 
affinity columns (1 mL, drained resin) were prepared with immo-
bilized 10G1.5, and artery wall apoA1 was purified from individual 
samples of aortic homogenates under conditions that quantitatively 
recovered apoA1, as confirmed with the use of Western blot analyses 
of column fractions.
LCAT Activity 
Human recombinant LCAT was prepared and purified from culture 
medium of a CHO cell line (generously provided by John Parks, 
Wake Forest University, Winston-Salem, NC) with stable expression 
of human LCAT.21 LCAT activity was determined by calculating the 
conversion efficiency of [3H]cholesterol to [3H]cholesteryl ester after 
lipid extraction of the reaction mixture followed by thin-layer chro-
matography.22 Fractional cholesterol esterification was calculated as 
disintegrations per minute in cholesterol esters divided by disintegra-
tions per minute in cholesterol esters plus free cholesterol. The frac-
tional cholesterol esterification rate was expressed as units of activity 
(nanomoles of cholesterol ester formed per hour per nanogram of 
LCAT) per microgram apoA1 protein.
Cholesterol Efflux Activity 
Cholesterol efflux experiments were performed according to estab-
lished procedures.23 The cholesterol efflux was calculated as the total 
radioactivity in the medium/(medium radioactivity plus cell radioac-
tivity). Results are expressed as a percentage relative to cholesterol 
efflux measured with the use of human apoA1 isolated from healthy 
donors (n=5) as control.
HDL Imaging
HDL was dual-labeled and incubated with mouse peritoneal mac-
rophages to individually monitor the fate of phospholipid versus 
protein components of the particle as follows. Briefly, the protein 
component of isolated human HDL was first labeled with Alexa 
Fluor 633 reactive dye kit (Molecular Probes, Eugene, OR) accord-
ing to the manufacturer’s instructions. HDL lipid was next labeled 
by first forming a phospholipid film of NBD-PE by evaporation of a 
1:4 methanol:chloroform solution overnight under vacuum and then 
rehydrating the film with Alexa Fluor 633–labeled HDL in prefil-
tered PBS and 4 cycles of alternating rounds of sonication at 0ºC 
for 1 minute, followed by a 1-minute interval on ice. Dual-labeled 
HDL was centrifuge filtered and washed numerous times with PBS 
before incubation with macrophages. Thioglycolate-elicited perito-
neal macrophages from C57Blk/6J mice were collected and cultured 
as described.24 Dual-labeled HDL (125 µg protein per milliliter) was 
incubated with cells at 37°C for 1 hour, and then images were cap-
tured on a Zeiss LSM 510 Meta confocal microscope.
Proteomic Analyses
To confirm that the protein recovered after immunoaffinity isolation 
(with the use of mAb 10G1.5) from normal aortic tissue homog-
enate was apoA1, the major SDS-PAGE gel bands at molecular 
weights 25 and 50 kDa were excised. The samples were first treated 
with dithiotheotol/iodoacetamide (Sigma, St Louis, MO) to carb-
amidomethylate any cysteines in the protein(s), and then proteins 
were digested with the use of Mass Spec grade trypsin (Promega, 
Madison, WI) at 37°C overnight. Tryptic peptides were loaded onto 
an IntegraFrit sample trap (ProteoPep C18, 300 Å, 150 μm×2.5 cm, 
New Objective, Woburn, MA) at 1 μL/min with 5% acetonitrile and 
0.1% formic acid to desalt the samples. The peptides were subse-
quently eluted through a column (75 μm×15 cm) packed in-house 
with XperTek 218TP, C18, 300 Å pore size, 150 μm particle size 
(Cobert Associates, St Louis, MO) at 200 nL/min with the use of 
a Proxeon Easy-nLC II system (Thermo Scientific, Waltham, MA) 
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with a gradient of 5% to 65% acetonitrile, 0.1% formic acid over 
120 minutes into a LTQ-Orbitrap Velos mass spectrometer (Thermo 
Scientific, Waltham, MA). Peak lists were generated with the use of 
Proteome Discoverer 1.1 (Thermo Fischer Scientific, Waltham, MA). 
The resulting Unified Search Files (*.srf) were searched against the 
Uniprot FASTA of all apolipoproteins and also against a human pro-
tein database downloaded from the European Bioinformatic Institute 
(release: 2013_02). Modifications used for searches included carb-
amidomethylated cysteine (fixed), oxidized methionine and tryp-
tophan (variable), 3-chlorotyrosine, and 3-nitrotyrosine (variable). 
Only strictly tryptic peptides with a maximum of 2 missed cleavage 
sites were allowed in the database searches. Monoisotopic precursor 
ions were searched with a tolerance of 100 ppm with 0.8 Da for the 
fragment ions on the data obtained from the hybrid LTQ-Orbitrap 
Velos mass spectrometer. Unidentified fragment ions in all frag-
mentation spectra were manually validated with the use of Protein 
Prospector (University of California, San Francisco).
Statistical Analysis
Nonparametric statistical methods were used to determine statisti-
cal differences attributable to sampling numbers. The Wilcoxon rank 
sum test was used for 2-group comparisons, and the Kruskal-Wallis 
test was used for multiple-group comparisons (>2 groups). In cases in 
which the Kruskal-Wallis test was performed for multiple-group com-
parisons and found to be significant (P<0.05), multiple- comparison 
procedures such as the Dunn test were used for pairwise comparison 
between groups and controls. The Wilcoxon rank sum test was also 
used for pairwise comparison. Where indicated, the 1-sample robust 
Hotelling T2 test was used to determine statistical significance when 
enzymatic activity between the control group and experimental group 
was compared.
Results
mAb 10G1.5 Recognizes ApoA1 Equally Well in 
its Lipid-Free or HDL-Associated, Native, and 
Oxidized Forms
We initially sought to accurately quantify and immunoaffin-
ity isolate apoA1 from artery wall tissue homogenate (from 
both normal and atherosclerotic lesions). We reasoned that 
this would require a sufficiently tight binding antibody that 
demonstrated minimal recognition bias between lipidated ver-
sus nonlipidated forms of the lipoprotein, as well as oxidized 
versus nonoxidatively modified forms. Examination of every 
commercially available antibody we could find (both mono-
clonal and polyclonal) showed significant bias in recognizing 
one form or another (typically recognition of oxidized forms 
preferentially, and with inadequate affinity). Figure 1A illus-
trates the biases observed with 3 characteristic commercial 
antibodies (2 polyclonal and 1 mouse mAb). Despite equal 
mass of protein loaded into adjacent lanes from native ver-
sus oxidized apoA1, and HDL versus oxidized HDL, the 
commercial antibodies show varied intensity of staining 
(eg, commercial antibody 1 shows oxidized HDL>oxidized 
apoA1>>apoA1 or HDL; commercial antibody 2 shows 
oxidized apoA1>oxidized HDL>>apoA1 or HDL; and 
commercial antibody 3 shows oxidized apoA1 or oxidized 
HDL>>apoA1 or HDL). We therefore initially sought to 
develop a suitable antibody that met our strict apoA1 recog-
nition criteria. Purified delipidated human apoA1 (isolated 
from plasma HDL) was injected into several apoa1−/− mice. 
After screening >5000 hybridoma clones for their ability to 
recognize apoA1 forms equally well, a small number (4) met 
our screening program requirements. One mAb, 10G1.5, was 
selected on the basis of specific activity of recognition by 
ELISA, immunoblot analysis, its ability to immunoprecipitate 
apoA1, and the growth characteristics of the hybridoma clone. 
Figure 1B illustrates that mAb 10G1.5 recognizes native 
apoA1 and apoA1 reconstituted into HDL particles equally 
well. Furthermore, mAb 10G1.5 recognizes apoA1 in native 
versus oxidized forms equivalently, with the use of a wide vari-
ety of oxidation schemes (Figure 1B). We further examined 
the ability of mAb 10G1.5 to quantify different concentrations 
of purified apoA1 (lipid-poor) versus equivalent amounts of 
Figure 1. Apolipoprotein A1 (apoA1) or apoA1 in reconstituted 
high-density lipoprotein (HDL) was either left untreated or 
oxidized at a 5:1 molar ratio of oxidant to apoA1, as described in 
Methods. A, Equal amounts of apoA1 were separated on 5% to 
15% reducing SDS-PAGE gels, and proteins were transferred to 
membranes for Western blot detection with the use of 3 distinct 
commercial antibodies (Ab), as indicated, or the monoclonal 
antibody (mAb) 10G1.5. Monomeric and multimeric apoA1 
immunoreactive bands are apparent, and molecular weight 
markers are indicated. B, Demonstration that apoA1-specific 
mAb 10G1.5 recognizes all forms of apoA1 (lipid-free and HDL 
associated, nonoxidized and oxidized [ox]) equally well. ApoA1 
(open bars) or reconstituted HDL (rHDL; filled bars) prepared 
from apoA1 or their oxidized versions using the oxidation 
systems as indicated were coated at 0.5 µg/mL into ELISA 
plates in triplicate and probed with 10 ng/mL anti-apoA1 mAb 
10G1.5. ELISA assays were performed as described in Methods. 
Reactions were stopped with 0.1 N HCl, and absorbance at 450 
nm was determined. HRP indicates horseradish peroxidase; 
MPO, myeloperoxidase. C, Lipid-free apoA1, isolated human 
plasma HDL, or the sub-HDL populations HDL2 and HDL3 
were each loaded (in triplicate for each data point) onto 5% 
to 15% reducing SDS-PAGE gels at the indicated amounts, 
and then apoA1 was quantified by immunoblot with the use of 
mAb 10G1.5, as described in Methods. All values represent the 
average of triplicate determinations; error bars indicate SD.
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total apoA1 in either isolated human HDL (total) or the indi-
vidual HDL subfractions HDL2 or HDL3 (Figure 1C). As 
can be seen, mAb 10G1.5 displayed nearly identical ability 
to quantify apoA1 in its varied lipid-free and lipidated forms 
over a range of masses. On the basis of the observed unbiased 
recognition of all apoA1 forms, we refer to this antibody as 
“anti-total” apoA1. This mAb was used throughout the stud-
ies described below to detect, immunoaffinity purify, and 
quantify apoA1 recovered from plasma, atherosclerotic lesion 
homogenates, and normal artery wall homogenates.
The Majority of ApoA1 Isolated From Lesions Is 
Highly Cross-Linked and Not HDL Associated
The particle distribution of apoA1 within human atheroscle-
rotic lesions has not been reported. We therefore homogenized 
human aortic atherosclerotic lesions (n=10 different subjects) 
and used sequential buoyant density ultracentrifugation to 
initially remove the VLDL/LDL-like fraction (d<1.063) and 
then recover both the HDL-like fraction (1.063≤d≤1.21) and 
the LPD fraction (density >1.21), as described in Methods. 
Samples were first examined on gradient (5% to 15%) SDS-
PAGE separations with the use of Sypro Ruby Red protein 
staining, which shows minimal protein-to-protein differ-
ences in staining; equally stains lipoproteins, glycoproteins, 
and other difficult-to-stain proteins; and does not interfere 
with subsequent mass spectrometry analyses. Visual inspec-
tion showed a complex protein mixture, with an unknown 
band migrating at ≈27 kDa, the molecular weight of apoA1 
(Figure 2A). Western analysis with anti-total apoA1 antibody 
(mAb 10G1.5) of a membrane containing transferred pro-
teins from a parallel-run duplicate gel readily detected within 
lesion homogenates a band at the molecular weight of the 
apoA1 monomer (Figure 2B). Remarkably, the vast majority 
of apoA1 within the aortic lesion was observed to be present 
not within the HDL-like fraction but rather within the LPD 
fraction (Figure 2B). After substantial increase in exposure 
of the immunoblot, apoA1 was detected within the HDL-like 
particle fraction (Figure 2C). Also notable within the immu-
noblots were prominent slower migrating forms of immuno-
reactive apoA1-containing protein bands at molecular weights 
of ≈50, ≈75, and ≈100 kDa present in particular within the 
starting material (homogenate) and the LPD fraction (d>1.21) 
but noticeably diminished in the HDL-like particle fraction 
(1.063≤d≤1.21). The sizes of these slower migrating apoA1-
immunoreactive bands are consistent with the sizes of oxida-
tively cross-linked dimeric and multimeric apoA1 forms.
Quantification of the distribution of protein and apoA1 forms 
recovered within homogenates from multiple distinct human 
atherosclerotic plaque–laden aorta (n=10) is shown in Figure 3. 
The majority (81.0±5.6%) of the total protein in the lesion 
homogenate was found in the LPD fraction, whereas the HDL-
like fraction contained only 1.7±0.2% (Figure 3A). Quantitative 
analysis of the anti-total apoA1–specific immunoblots indicated 
that nearly all of the apoA1 isolated from lesions was lipid-poor 
and found within the LPD fraction (d>1.21), where 0.7±0.4 
mg apoA1 per gram wet weight of lesion material was recov-
ered (Figure 3B), corresponding to 92.4±4.1% of total apoA1 
in the artery wall (Figure 3C). Surprisingly, only a nominal 
amount (<3%) of apoA1 within the artery wall (lesions) was 
recovered in the HDL-like particle fraction (Figure 3B and 3C). 
Yet another remarkable finding was the abundance of slower 
migrating immunoreactive apoA1-containing bands migrat-
ing with molecular masses of dimeric, trimeric, and tetrameric 
forms of apoA1 within the lesion homogenates. Quantification 
of these apoA1-immunoreactive bands revealed that approxi-
mately two thirds (66±4%) of apoA1 within lesions was 
oxidatively cross-linked, and the cross-linked forms were pref-
erentially present in the LPD fraction (Figure 3D). Proteomics 
analyses of anti-total apoA1 (mAb 10G1.5) immunoprecipi-
tated higher-molecular-weight apoA1 forms confirmed that 
these bands also were predominately composed of apoA1 (see 
below). Total apoA1 present in the aortic tissues reported is 
Figure 2. Apolipoprotein A1 (apoA1) from human atherosclerotic 
lesions is not located on high-density lipoprotein (HDL)–like 
particles and is heavily cross-linked. Proteins in atherosclerotic 
lesion homogenate or after buoyant density ultracentrifugation 
fractionation into HDL-like particles and lipoprotein-depleted 
(LPD) fractions from the indicated density ranges were 
separated on 5% to 15% reducing SDS-PAGE gels. A, Sypro 
Ruby–stained gel of the indicated protein samples (10 µg) 
from homogenate and the indicated density ranges obtained 
from different atherosclerotic lesion tissue samples (n=5). 
B, Western blot membrane of a duplicate run gel as in A with 
2.4, 0.4, and 2.4 µg of homogenate, HDL-like, and LPD fraction 
proteins, respectively, probed with anti-total apoA1 monoclonal 
antibody (mAb) 10G1.5. C, Overexposure of Western blot in B 
to show apoA1 in HDL-like fraction. Monomeric and dimeric 
apoA1 immunoreactive bands and molecular weight markers 
are indicated.
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actually modestly underestimated because we know that under 
the conditions used, ≈15% to 20% of the total apoA1 remains 
unrecovered in the “pellet” from the initial tissue homogenate. 
This modest loss appeared acceptable because control studies 
with repeated homogenization of the pellet and fractionation of 
the recovered material revealed, within both crude homogenate 
and subsequent buoyant density isolated fractions, banding 
patterns and results that were virtually identical to the original 
homogenate and fractions on the basis of both protein staining 
and Western blot analyses (data not shown).
ApoA1 Is Markedly Enriched in Lesions, and 
Normal Aortic Tissue ApoA1 Similarly Is Lipid-
Poor and Highly Cross-Linked
Our initial studies focused on apoA1 within atherosclerotic 
lesions. However, given the surprising finding that virtually 
all apoA1 within aortic lesions was not on an HDL particle, 
and fully two thirds of all apoA1 within lesions was cross-
linked, we decided to examine apoA1 within normal aortic 
tissue for comparison. Normal aortic tissue was obtained at 
time of organ harvest from transplant donors. For illustra-
tive purposes, images of a typical normal aortic specimen 
and a typical atherosclerotic plaque–laden aortic specimen 
are shown in Figure 4A. Homogenates of normal aortic tis-
sue (n=5) were prepared and fractionated by buoyant density 
ultracentrifugation as described in Methods. Fractionation of 
protein from normal artery and lesion homogenates on (5% to 
15%) gradient reducing SDS-PAGE gels stained with Sypro 
Ruby Red for protein revealed that although there are simi-
larities in the protein banding pattern, the pattern is noticeably 
different in normal versus lesion homogenates (Figure 4B). 
Notably, immunoblot probing with apoA1-specific anti-total 
apoA1 (mAb 10G1.5) of parallel SDS-PAGE gels transferred 
to membranes showed that compared with lesion-derived 
homogenates, there is very little immunoreactive apoA1 in 
homogenates prepared from normal aortic tissue (Figure 4C). 
Because extremely low levels of apoA1 were observed 
within normal artery wall tissue, and especially the HDL-
like fraction, an increased protein amount was loaded onto 
SDS-PAGE gels to permit visualization by Western blot and 
comparison of HDL-like and LPD fractions from the normal 
artery wall homogenate (Figure 4D). The majority of protein 
in the normal artery wall homogenate was found to be in the 
LPD fraction (Figure I in the online-only Data Supplement). 
As observed for aortic lesion apoA1, a significant portion of 
apoA1 was lipid-poor and recovered within the LPD frac-
tion. Furthermore, there was a high degree of immunoreactive 
apoA1 forms in the normal artery wall that migrate at higher 
molecular weights, consistent with that of oxidatively cross-
linked apoA1 dimer and higher multimeric forms, particularly 
within the LPD fraction (Figure 4D).
Quantification of apoA1-specific immunoblots (with 
volumes of starting homogenate and density cut fractions 
recovered taken into account) revealed that the total apoA1 
recovered per gram of wet weight aortic tissue from normal 
artery wall was 120-fold less than that recovered from lesion-
laden aorta (Figure 4E; note log scale for y axis). Remarkably, 
the distribution of apoA1 within normal artery resembled those 
found in the same fractions from atherosclerotic lesions, with 
only 3% of apoA1 being HDL associated and ≈92% of the 
total apoA1 present in the normal artery wall residing in the 
LPD fraction (Figure 4F). Similar to our observation within 
lesions, nearly half (43.4±13.9%) of the total apoA1 within 
the normal artery wall was cross-linked and was observed to 
reside not on the HDL-like particle (3.6±2.6%) but in the LPD 
fraction (61.4±23.0%; Figure 4G).
Because the levels of apoA1 in the normal artery wall–
derived homogenates were so low, we wanted to verify that 
the bands detected on Western blots with the use of mAb 
10G1.5 were in fact apoA1. We therefore immunopurified 
apoA1 from normal aortic tissue homogenates (n=5) using 
10G1.5 (as described in Methods), and immunoaffinity iso-
lated proteins were separated on a gradient nonreducing 
(5% to 15%) SDS-PAGE gel and stained for protein. The 
major protein bands observed corresponded to doublet bands 
Figure 3. Particle distribution of apolipoprotein A1 (apoA1) 
obtained from human atherosclerotic artery wall. A, Percentages 
of total protein in starting homogenate and in buoyant density 
ultracentrifugation fractions for low-density lipoprotein (LDL)–like, 
high-density lipoprotein (HDL)–like, and lipoprotein-depleted 
(LPD) fractions determined by bicinchoninic acid protein assay 
are indicted. B, ApoA1 (mg) recovered per gram of lesion tissue 
(wet weight) in the HDL-like and LPD fractions. C, Percent apoA1 
to total apoA1 from atherosclerotic lesion homogenate present 
in the HDL-like and LPD fractions. D, Cross-linked apoA1/total 
apoA1 within each fraction as a percentage was determined 
by quantitative Western blot analysis of apoA1 immunoreactive 
bands in Figure 2B and additional blots (not shown). Values were 
determined from samples (n=10); error bars represent SD. Mean 
values are indicated by a heavy horizontal line. Kruskal-Wallis 
test was used in A and D and found to be significant (P=0.0001 
and P=0.0003, respectively). Dunn test was used to adjust for 
multiple comparisons, and Wilcoxon rank sum test was used in 
pairwise comparisons. Actual P values are listed when P<0.05.
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migrating at ≈25 and ≈50 kDa (Figure II in the online-only 
Data Supplement). These were individually excised and 
digested with trypsin for mass spectrometry analyses, as 
described in Methods. Tandem mass spectrometry analyses 
of tryptic peptides for each excised band revealed apoA1 as 
the dominant protein within each, with 40% to 62% peptide 
coverage in each of the gel-excised bands (Tables I through 
IV in the online-only Data Supplement).
Plasma ApoA1 Is Predominantly HDL Associated 
and Has Decreased ApoA1 Cross-Links in the HDL-
like Fraction Compared With the LPD Fraction
Given the surprising HDL particle distribution and cross-link 
prevalence of apoA1 found in the artery wall (Figures 2–4) 
and the known preponderance of apoA1 within the HDL 
fraction in plasma, we examined the distribution of apoA1 
in plasma using the same anti-total apoA1 mAb (10G1.5). 
Plasma from normal healthy consenting donors was frac-
tionated by sequential buoyant density ultracentrifugation as 
described in Methods. The indicated amounts of protein from 
the starting material plasma, HDL-rich fraction, and LPD 
fractions were run on gradient (5% to 15%) reducing SDS-
PAGE gels and stained with Coomassie Blue (Figure 5A) or 
transferred for immunoblot analyses with anti-apoA1 mAb 
10G1.5 (Figure 5B). As expected, the dominant immuno-
reactive band observed migrates at ≈27 kDa, correspond-
ing to the apoA1 monomer, and is predominantly recovered 
within the HDL fraction (≈83%; Figure 5B and 5D). Unlike 
apoA1 recovered from the artery wall, there is little noticeable 
higher-molecular-weight cross-linked apoA1 in the starting 
plasma, particularly within the circulating HDL fraction. Of 
note, however, the content of apoA1 cross-linked within the 
LPD fraction was found to be 3-fold higher than that observed 
within the HDL fraction but still represented only a small 
minority (6.0±1.8%) of the total apoA1 within that fraction 
(Figure 5E; longer exposures of plasma and LPD fractions are 
shown in Figure III in the online-only Data Supplement).
ApoA1 Isolated From Atherosclerotic Lesions  
Is Dysfunctional 
In a final series of experiments, apoA1 was isolated from 
additional atherosclerotic plaque–laden aortic tissues (n=10 
Figure 4. Apolipoprotein A1 (apoA1) obtained from 
the artery wall is not on a high-density lipoprotein 
(HDL)–like particle and behaves in a manner 
similar to that isolated from atherosclerotic lesions. 
A, Representative aortic tissue from normal and 
atherosclerotic human artery wall. B, Sypro Ruby–
stained 5% to 15% SDS-PAGE gel of normal and 
atherosclerotic lesion homogenate (n=5) proteins 
(5 µg). C, Western blot of duplicate gel as in A 
with the indicated amount of protein per lane (n=5) 
probed with anti-total apoA1 monoclonal antibody 
(mAb) 10G1.5. D, Western blot of normal artery 
wall proteins (30 µg) from homogenate (sample 1, 
pooled samples 2 and 3, and pooled samples 4 
and 5), HDL-like, and lipoprotein-depleted (LPD) 
fractions probed with anti-total apoA1 mAb 10G1.5 
to show apoA1 and cross-linked apoA1. E, ApoA1 
(mg) recovered per gram of normal aortic tissue (wet 
weight) in the HDL-like and LPD fractions. F, ApoA1 
to total apoA1 as a percentage from normal aortic 
tissue homogenate present in the HDL-like and LPD 
fractions. G, Cross-linked apoA1/total apoA1 within 
each fraction as a percentage was determined 
by quantitative Western blot analysis of apoA1 
immunoreactive bands in C and D. Monomeric 
and dimeric apoA1 are indicated. Values were 
determined from samples of n=5 (C) and n=3 in 
(D) and additional blots (not shown); error bars 
represent SD. Mean values are indicated by a heavy 
horizontal line. Kruskal-Wallis test was used in G 
and found to be significant (P=0.006). Wilcoxon 
rank sum test was used in pairwise comparisons to 
determine statistical differences. Actual P values are 
listed when P<0.05.
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subjects) by individual immunoaffinity columns composed of 
immobilized anti-total apoA1 (mAb 10G1.5), as described in 
Methods. Immunoisolated apoA1 was quantified, and equiva-
lent amounts of apoA1 protein were recovered from lesions 
from each sample, or apoA1 purified from plasma HDL (as 
a control) was incubated with cholesterol-loaded murine 
macrophage RAW264.7 cells to quantify cholesterol efflux 
activity. Remarkably, every apoA1 sample recovered from 
plaque-laden aorta demonstrated lower cholesterol accep-
tor activity, showing 78.9± 6.0% less total cholesterol efflux 
capacity compared with control apoA1 purified from plasma 
HDL from healthy donors (Figure 6). In parallel studies, each 
of the lesion apoA1 samples was incorporated into reconsti-
tuted HDL by cholate dialysis method and further purified 
by gel filtration fast protein liquid chromatography, and then 
comparable amounts (5 µg apoA1 mass) of each rHDL were 
examined for LCAT activity and compared with rHDL gen-
erated from apoA1 purified from plasma HDL from healthy 
volunteers. rHDL formed with lesion apoA1 demonstrated 
significantly less (89.6±5.0%) LCAT activity compared with 
rHDL formed from control apoA1 (Figure 6). Thus, apoA1 
in atherosclerotic plaque–laden aorta is markedly functionally 
impaired (ie, “dysfunctional”) with respect to both cholesterol 
acceptor and LCAT activities.
Discussion
The present studies reveal multiple remarkable findings about 
apoA1 within the artery wall. First, the vast majority of apoA1 
within both normal and atherosclerotic human arterial tissue, 
in contrast to within the circulation, is lipid-poor (ie, in the 
LPD fraction, d>1.21) and does not reside on an HDL-like 
(1.063≤d≤1.21) particle. Second, the content of apoA1 in 
atherosclerotic lesions is >100-fold higher than that observed 
within normal artery wall. Third, the majority of apoA1 within 
arterial tissues (both normal and atherosclerotic) is oxidatively 
cross-linked. Fourth, apoA1 within arterial tissues is dysfunc-
tional, with ≈80% reduction in cholesterol acceptor activity 
and ≈90% reduction in capacity to activate LCAT. Fifth, the 
majority of oxidatively cross-linked apoA1 within the circula-
tion is not HDL particle associated but rather resides within 
the LPD fraction (d>1.21). Collectively, the present studies 
thus argue that examination of total apoA1 and HDL func-
tion within the circulation may not adequately represent what 
is occurring within the artery wall, especially with respect to 
cholesterol acceptor and LCAT activities. Moreover, the over-
all strategy applied in the present studies may prove useful 
in the examination of other posttranslational modifications to 
apoA1, such as glycation, and site-specific oxidative modi-
fications as antibodies become available. Finally, the present 
studies suggest that the common practice of isolating circulat-
ing HDL for study of its biological properties and discarding 
the lipid-poor (non–HDL associated) apoA1 may in fact be 
throwing out the very fraction (lipid-poor) that more closely 
Figure 5. Apolipoprotein A1 (apoA1) in plasma is on high-
density lipoprotein (HDL) particles and behaves differently 
than artery wall–derived apoA1. Plasma from normal healthy 
human volunteers (n=5) was fractionated by buoyant density 
gradient centrifugation. A, Coomassie Blue–stained 5% to 15% 
SDS-PAGE gel of plasma, high-density lipoprotein (HDL), and 
lipoprotein-depleted (LPD) fraction proteins. B, Western blot 
analysis of proteins on membrane from a duplicate fractionated 
protein gel probed with anti-total apoA1 monoclonal antibody 
(mAb) 10G1.5 shows apoA1 predominantly in the HDL fraction 
and not cross-linked. C, Percentage of total protein recovered 
in starting material and in very-low-density lipoprotein 
(VLDL)+low-density lipoprotein (LDL), HDL-like, and LPD 
fractions. Quantitative analyses of B and overexposed B reveal 
percentage of apoA1 to total apoA1 present in the plasma HDL 
and LPD fractions in D and cross-linked apoA1/total apoA1 
within plasma, HDL, and LPD fractions in E. Values (C and D) 
were determined from samples (n=5). Error bars represent SD; 
mean is indicated by a heavy horizontal line. Kruskal-Wallis test 
was used to determine statistical differences for data presented 
in C and E, which were found to be significant (P=0.0002 and 
P=0.01, respectively). Dunn test was used to adjust for multiple 
comparisons in C, and Wilcoxon rank sum test was then used for 
pairwise comparisons. Actual P values are listed.
Figure 6. Functional characterization of lesion apolipoprotein 
A1 (apoA1). Macrophage cholesterol efflux activity and lecithin-
cholesteryl acyltransferase (LCAT) activity were measured in 
apoA1 immunoaffinity purified from human atherosclerotic-laden 
plaque (n=10 different subjects), as described in Methods. ApoA1 
isolated from plasma high-density lipoprotein recovered from 
healthy donors (n=3) and reconstituted high-density lipoprotein 
formed from these apoA1 particles served as controls for total 
efflux activity and LCAT activity, respectively. Bars represent 
triplicate determinations; error bars represent SD. P values 
represent comparison between subject samples vs control 
apoA1 and were determined with the use of the 1-sample robust 
Hotelling T2 test.
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reflects the environment within the artery wall. Of note, the 
extent of oxidatively cross-linked apoA1 within the lipid-poor 
(LPD) fraction of plasma was ≈3-fold enriched relative to the 
HDL-like fraction (Figure 5E). On the basis of the cumulative 
results herein, one might speculate that dysfunctional forms of 
HDL monitored within the circulation will most likely reside 
not on the HDL particle itself but as lipid-poor forms in the 
LPD fraction (d>1.21). It is notable that the apoA1 found 
within the artery wall, which was predominantly within the 
LPD fraction in both atherosclerotic lesions and normal artery 
wall tissue, is remarkably highly cross-linked (50% to 70%). 
This value is even higher than previously observed in Western 
blots (though cross-linking was not quantified per se) in stud-
ies examining apoA1 oxidation levels in the artery wall based 
on buoyant density recovery of HDL-like particles.8 Through 
use of stable isotope dilution mass spectrometry–based 
approaches, these studies suggested that an upper bound-
ary of up to 1 of every 2 HDL-like particles recovered from 
the artery wall carried an oxidative modification from either 
myeloperoxidase- or NO-derived oxidants.8
One question the present studies raise is how apoA1 becomes 
>100-fold enriched within atherosclerotic plaques compared 
with normal artery. A second question is how artery wall 
apoA1 is rendered lipid-poor when the vast majority of apoA1 
that diffuses into the artery wall tissue from the circulation 
resides within the HDL particle. To address these questions, 
we performed preliminary confocal microscopy studies in 
which HDL was isolated from peripheral blood of healthy vol-
unteers and subsequently doubly labeled (protein with Alexa 
Fluor 633 [red] and phospholipid with NBD-PE [green], as 
described in Methods). Brief incubation of the double-labeled 
HDL with macrophages led to virtually all of the phospholipid 
fluorophore being rapidly taken up within the macrophage, 
whereas the protein (predominantly apoA1) remained on the 
cell surface (data not shown). Such preliminary results pro-
vide a rationale to speculate that selective uptake of lipids may 
contribute as a mechanism for rapidly depleting the HDL par-
ticle of not just cholesterol but also phospholipid, leaving the 
lipid-poor apoA1 behind in the extracellular space. Lipid-poor 
or lipid-free forms of apoA1 are recognized as the preferred 
substrate of ABCA1.5,25–27 Therefore, a question that logically 
follows is why the lipid-poor apoA1 form within the artery 
wall is such a poor cholesterol acceptor (Figure 6). In past 
studies, we have shown that oxidative modification of apoA1 
by myeloperoxidase-generated oxidants markedly impairs 
its ABCA1-dependent cholesterol efflux activity.8–10,13 Other 
studies have also reported that carboxy-terminal proteolized 
(ie, “clipped”) apoA1 can be recovered from aortic tissue 
that fails to efficiently bind lipid.28,29 In the present studies, 
however, we did not see substantial levels of lower-molecu-
lar-weight forms of apoA1 in tissue homogenates once we 
exercised extreme care in keeping tissues ice-cold and, more 
importantly, included an extensive cocktail of protease inhibi-
tors during tissue dissection, homogenization, and fraction-
ation, as outlined in Methods. Given the extensive oxidative 
cross-linking observed in total apoA1 within lesions, oxida-
tive posttranslational modifications of apoA1 likely explain in 
large part why the lipoprotein, at least within lesions, remains 
lipid-poor. It should also be noted, however, that Parks and 
colleagues26 reported that interaction of apoA1 with ABCA1 
results in lipid-poor pre-β HDL migrating forms of apoA1 that 
themselves are poor substrates for subsequent repeat or further 
lipidation by ABCA1, suggesting the requirement of an addi-
tional (non–ABCA1-mediated) process for further maturation 
into an HDL particle. Whether this contributes to the present 
results is unclear. Similarly, if an additional process is needed 
for further lipidation of lipid-poor apoA1 after initial interac-
tion with ABCA1, whether this process is somehow lacking 
or inhibited within the artery wall requires further study. It 
also would have been interesting to test whether rHDL made 
with apoA1 isolated from the vessel wall was also defective 
in either ABCG1 or passive efflux compared with HDL made 
with plasma-derived apoA1. However, given the limitations in 
the amount of apoA1 able to be purified from human arterial 
tissues, these studies will need to await further investigation.
As for the mechanism(s) for apoA1 accumulation within 
lesions compared with normal artery, we have no clear answers 
from the present studies. We can speculate that the extensive 
oxidative cross-linking noted here may help to provide an 
answer, as well as mass spectrometry studies in the past.8–10,13 
Oxidatively modified proteins tend to be less soluble and rela-
tively protease resistant and might thus be “retained” within 
the subendothelial space, particularly within the hydrophobic 
environment of the atherosclerotic plaque. The phenomenon of 
lipoprotein retention within the subendothelial compartment 
of the artery wall has been suggested previously. Originally 
proposed for apoB lipoproteins, retention or trapping of LDL 
particles in the initial stages of atherosclerosis is suggested to 
cultivate formation of modified LDL, which may incite bio-
logical and inflammatory responses that initiate or advance the 
atherosclerotic process.30 Progressive apoB lipoprotein reten-
tion through the actions of secretory acid sphingomyelinase 
and lipoprotein lipase are thought to lead to accelerated lesion 
progression.31,32 Although we have no data to implicate lipase 
activation at present in depleting lipids from HDL within the 
artery wall leading to lipid-depleted forms, the presence of 
similar phospholipids on HDL suggests that a similar reten-
tion scheme for apoA1 lipoprotein retention is feasible and 
could thus contribute to the observed accumulation of apoA1 
in artery wall lesions over time, in addition to enhanced lipid 
and sterol uptake into macrophages producing foam cells. 
Other studies have also shown that increased endothelial cell 
permeability in atherosclerotic lesions could lead to increased 
LDL and HDL migration into the diseased vessel wall and 
accelerate the retention process.33–35
Although multiple studies have noted extensive oxidative 
modification of apoA1 recovered from the artery wall,8–11,13–
16,36
 there has been disagreement about which residues are 
the main sites of oxidation. Our prior proteomic mapping 
studies used polyclonal antibodies (chicken anti-apoA1 or 
anti-HDL) to immunoprecipitate apoA1 from arterial tissue 
homogenates.13,16 In contrast, proteomic mapping studies from 
alternative groups typically have used buoyant density isola-
tion to recover the HDL-like particle fraction within lesion 
homogenates.11,15 On the basis of the present studies using the 
mAb 10G1.5, which was developed specifically to allow both 
recovery and equal quantification of apoA1 in lipid-free ver-
sus lipidated and native versus oxidized forms, it is now clear 
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that analysis of recovered HDL-like particles from arterial tis-
sues only examines a very small fraction (<3%) of the total 
apoA1 within the artery wall. Whether the small amount of 
apoA1 (and its associated proteome) recovered in an HDL-
like particle from the artery wall provides a “snapshot” of the 
apoA1 on its way to particle “disintegration” and formation 
of the lipid-poor apoA1 that is the predominant form remains 
to be determined. The present studies suggest that results that 
focus on HDL-like particles recovered from the artery wall 
need to be interpreted within the context of recognizing their 
minor quantitative contribution to total apoA1 in the artery 
wall. An interesting question, although not examined in the 
present studies, is whether changes in the HDL-associated 
proteome within the circulation observed in subjects with car-
diovascular disease or within subjects at heightened risk for 
cardiovascular disease37–41 have any relevance to the marked 
changes in the environment of apoA1 observed within the 
artery wall.
The complexity surrounding the role of the HDL parti-
cle in the pathogenesis of cardiovascular disease has been 
highlighted recently because of several high-profile clinical 
trial failures targeting raising of HDL cholesterol and recent 
Mendelian randomization studies on HDL cholesterol lev-
els.1,2,4,42–47 The present studies suggest that traditional HDL-
measured parameters within the circulation, such as HDL 
cholesterol and apoA1 mass, may not adequately reflect the 
biology of apoA1 occurring within the artery wall. Recent 
studies suggest that functional measures of cholesterol 
efflux activity within apolipoprotein B–depleted serum may 
serve as a superior surrogate for HDL function.48 However, 
this too has recently been questioned because the HDL 
particle was found to account for only a minority of the 
cholesterol acceptor activity in the cholesterol efflux activ-
ity assays performed.49 Furthermore, despite the reported 
inverse association between cholesterol efflux activity and 
prevalent cardiovascular disease, in a separate large clinical 
study of similar patients (ie, sequential subjects undergoing 
elective diagnostic coronary angiography), enhanced cho-
lesterol efflux activity was observed to be associated para-
doxically with increased prospective cardiovascular event 
risk.49 It is remarkable that what we now recognize as HDL 
was first described nearly a century ago.50 Yet, studies focus-
ing on HDL still continue to surprise us and reveal how little 
we know about its complex biology. The present and recent 
studies suggest that measurement in the circulation of HDL 
cholesterol, apoA1, or even cholesterol efflux activity may 
not adequately reflect what is happening within the artery 
wall. Rather, development of dysfunctional HDL assays that 
detect structurally specific modified forms of apoA1 formed 
in the artery wall but that diffuse back out into the circu-
lation may be what is needed to provide insights into the 
processes occurring within the artery wall.
Sources of Funding
This study was supported by National Institutes of Health grants 
P01HL098055, P01HL076491, and HL17964. This work was 
also supported in part by a grant from the LeDucq Fondation. Dr 
Hazen was also partially supported by a gift of the Leonard Krieger 
Foundation.
Disclosures
Dr Tang has previously received research grant support from Abbott 
Laboratories. Drs Hazen and Smith report being listed as coinventor 
on pending and issued patents held by the Cleveland Clinic relating 
to cardiovascular diagnostics. Dr Hazen reports having been paid as a 
consultant for the following companies: AstraZeneca Pharmaceuticals 
LP, Cleveland Heart Laboratory, Esperion, Lilly, Liposcience Inc, 
Merck & Co, Inc, Pfizer Inc, and Takeda. Dr Hazen reports receiv-
ing research funds from Abbott, Cleveland Heart Laboratory, and 
Liposcience Inc. Dr Smith reports having the right to receive royalty 
payments for inventions or discoveries related to cardiovascular diag-
nostics from Cleveland Heart Laboratory and being paid as a consul-
tant for Esperion. Dr Hazen reports having the right to receive royalty 
payments for inventions or discoveries related to cardiovascular diag-
nostics and the companies shown below: Cleveland Heart Laboratory, 
Frantz Biomarkers, LLC, Liposcience Inc, and Siemens. The other 
authors report no conflicts.
References
 1. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, 
Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, 
Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators. 
Effects of torcetrapib in patients at high risk for coronary events. N Engl J 
Med. 2007;357:2109–2122.
 2. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens 
P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with 
low HDL cholesterol levels receiving intensive statin therapy. N Engl J 
Med. 2011;365:2255–2267.
 3. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, 
Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray 
JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUT-
COMES Investigators. Effects of dalcetrapib in patients with a recent 
acute coronary syndrome. N Engl J Med. 2012;367:2089–2099.
 4. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic 
M, Jensen MK, Hindy G, Hólm H, Ding EL, Johnson T, Schunkert H, 
Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson 
G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, 
Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, 
Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, 
McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser 
V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, 
Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de 
Bakker PI, Klungel OH, Maitland-van der Zee AH, Peters BJ, de Boer 
A, Grobbee DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret 
NC, Hofker MH, Wijmenga C, Verschuren WM, Boer JM, van der Schouw 
YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, 
Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, 
Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann 
J, Diemert P, Willenborg C, König IR, Fischer M, Hengstenberg C, Ziegler 
A, Buysschaert I, Lambrechts D, Van de Werf F, Fox KA, El Mokhtari NE, 
Rubin D, Schrezenmeir J, Schreiber S, Schäfer A, Danesh J, Blankenberg 
S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, 
Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander 
O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, 
O’Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler 
D, Kathiresan S. Plasma HDL cholesterol and risk of myocardial infarc-
tion: a Mendelian randomisation study. Lancet. 2012;380:572–580.
 5. Rye KA, Barter PJ. Formation and metabolism of prebeta-migrating, lipid-
poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol. 2004;24:421–428.
 6. Chao FF, Amende LM, Blanchette-Mackie EJ, Skarlatos SI, Gamble W, 
Resau JH, Mergner WT, Kruth HS. Unesterified cholesterol-rich lipid par-
ticles in atherosclerotic lesions of human and rabbit aortas. Am J Pathol. 
1988;131:73–83.
 7. Tîrziu D, Dobrian A, Tasca C, Simionescu M, Simionescu N. Intimal 
thickenings of human aorta contain modified reassembled lipoproteins. 
Atherosclerosis. 1995;112:101–114.
 8. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, 
Schmitt D, Fu X, Thomson L, Fox PL, Ischiropoulos H, Smith JD, Kinter 
M, Hazen SL. Apolipoprotein A-I is a selective target for myeloperoxi-
dase-catalyzed oxidation and functional impairment in subjects with car-
diovascular disease. J Clin Invest. 2004;114:529–541.
 9. Wu Z, Wagner MA, Zheng L, Parks JS, Shy JM III, Smith JD, Gogonea V, 
Hazen SL. The refined structure of nascent HDL reveals a key functional 
1653
domain for particle maturation and dysfunction. Nat Struct Mol Biol. 
2007;14:861–868.
 10. Undurti A, Huang Y, Lupica JA, Smith JD, DiDonato JA, Hazen SL. 
Modification of high density lipoprotein by myeloperoxidase generates a 
pro-inflammatory particle. J Biol Chem. 2009;284:30825–30835.
 11. Pennathur S, Bergt C, Shao B, Byun J, Kassim SY, Singh P, Green PS, 
McDonald TO, Brunzell J, Chait A, Oram JF, O’brien K, Geary RL, 
Heinecke JW. Human atherosclerotic intima and blood of patients with 
established coronary artery disease contain high density lipoprotein dam-
aged by reactive nitrogen species. J Biol Chem. 2004;279:42977–42983.
 12. Hadfield KA, Pattison DI, Brown BE, Hou L, Rye KA, Davies MJ, 
Hawkins CL. Myeloperoxidase-derived oxidants modify apolipoprotein 
A-I and generate dysfunctional high-density lipoproteins: comparison 
of hypothiocyanous acid (HOSCN) with hypochlorous acid (HOCl). 
Biochem J. 2013;449:531–542.
 13. Zheng L, Settle M, Brubaker G, Schmitt D, Hazen SL, Smith JD, Kinter 
M. Localization of nitration and chlorination sites on apolipoprotein A-I 
catalyzed by myeloperoxidase in human atheroma and associated oxida-
tive impairment in ABCA1-dependent cholesterol efflux from macro-
phages. J Biol Chem. 2005;280:38–47.
 14. Peng DQ, Wu Z, Brubaker G, Zheng L, Settle M, Gross E, Kinter M, 
Hazen SL, Smith JD. Tyrosine modification is not required for myelo-
peroxidase-induced loss of apolipoprotein A-I functional activities. J Biol 
Chem. 2005;280:33775–33784.
 15. Shao B, Bergt C, Fu X, Green P, Voss JC, Oda MN, Oram JF, Heinecke 
JW. Tyrosine 192 in apolipoprotein A-I is the major site of nitration 
and chlorination by myeloperoxidase, but only chlorination mark-
edly impairs ABCA1-dependent cholesterol transport. J Biol Chem. 
2005;280:5983–5993.
 16. Peng DQ, Brubaker G, Wu Z, Zheng L, Willard B, Kinter M, Hazen SL, 
Smith JD. Apolipoprotein A-I tryptophan substitution leads to resistance 
to myeloperoxidase-mediated loss of function. Arterioscler Thromb Vasc 
Biol. 2008;28:2063–2070.
 17. Ståhlman M, Davidsson P, Kanmert I, Rosengren B, Borén J, 
Fagerberg B, Camejo G. Proteomics and lipids of lipoproteins iso-
lated at low salt concentrations in D2O/sucrose or in KBr. J Lipid Res. 
2008;49:481–490.
 18. Wu Z, Gogonea V, Lee X, Wagner MA, Li XM, Huang Y, Undurti A, May 
RP, Haertlein M, Moulin M, Gutsche I, Zaccai G, Didonato JA, Hazen 
SL. Double superhelix model of high density lipoprotein. J Biol Chem. 
2009;284:36605–36619.
 19. Matz CE, Jonas A. Micellar complexes of human apolipoprotein A-I with 
phosphatidylcholines and cholesterol prepared from cholate-lipid disper-
sions. J Biol Chem. 1982;257:4535–4540.
 20. Nelson DP, Kiesow LA. Enthalpy of decomposition of hydrogen peroxide 
by catalase at 25 degrees C (with molar extinction coefficients of H2O2 
solutions in the UV). Anal Biochem. 1972;49:474–478.
 21. Chisholm JW, Gebre AK, Parks JS. Characterization of C-terminal his-
tidine-tagged human recombinant lecithin:cholesterol acyltransferase. 
J Lipid Res. 1999;40:1512–1519.
 22. Parks JS, Gebre AK, Furbee JW. Lecithin-cholesterol acyltransfer-
ase: assay of cholesterol esterification and phospholipase A2 activities. 
Methods Mol Biol. 1999;109:123–131.
 23. Smith JD, Le Goff W, Settle M, Brubaker G, Waelde C, Horwitz A, Oda 
MN. ABCA1 mediates concurrent cholesterol and phospholipid efflux to 
apolipoprotein A-I. J Lipid Res. 2004;45:635–644.
 24. Piao ZH, Kim MS, Jeong M, Yun S, Lee SH, Sun HN, Song HY, Suh HW, 
Jung H, Yoon SR, Kim TD, Lee YH, Choi I. VDUP1 exacerbates bactere-
mic shock in mice infected with Pseudomonas aeruginosa. Cell Immunol. 
2012;280:1–9.
 25. Wang N, Silver DL, Costet P, Tall AR. Specific binding of ApoA-I, 
enhanced cholesterol efflux, and altered plasma membrane morphology in 
cells expressing ABC1. J Biol Chem. 2000;275:33053–33058.
 26. Mulya A, Lee JY, Gebre AK, Thomas MJ, Colvin PL, Parks JS. Minimal 
lipidation of pre-beta HDL by ABCA1 results in reduced ability to interact 
with ABCA1. Arterioscler Thromb Vasc Biol. 2007;27:1828–1836.
 27. Duong PT, Weibel GL, Lund-Katz S, Rothblat GH, Phillips MC. 
Characterization and properties of pre beta-HDL particles formed 
by ABCA1-mediated cellular lipid efflux to apoA-I. J Lipid Res. 
2008;49:1006–1014.
 28. Liu L, Bortnick AE, Nickel M, Dhanasekaran P, Subbaiah PV, Lund-Katz 
S, Rothblat GH, Phillips MC. Effects of apolipoprotein A-I on ATP-
binding cassette transporter A1-mediated efflux of macrophage phos-
pholipid and cholesterol: formation of nascent high density lipoprotein 
particles. J Biol Chem. 2003;278:42976–42984.
 29. Eriksson M, Schönland S, Yumlu S, Hegenbart U, von Hutten H, Gioeva 
Z, Lohse P, Büttner J, Schmidt H, Röcken C. Hereditary apolipopro-
tein AI-associated amyloidosis in surgical pathology specimens: iden-
tification of three novel mutations in the APOA1 gene. J Mol Diagn. 
2009;11:257–262.
 30. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the 
initiating process in atherosclerosis: update and therapeutic implications. 
Circulation. 2007;116:1832–1844.
 31. Gustafsson M, Levin M, Skålén K, Perman J, Fridén V, Jirholt P, Olofsson 
SO, Fazio S, Linton MF, Semenkovich CF, Olivecrona G, Borén J. Retention 
of low-density lipoprotein in atherosclerotic lesions of the mouse: evidence 
for a role of lipoprotein lipase. Circ Res. 2007;101:777–783.
 32. Devlin CM, Leventhal AR, Kuriakose G, Schuchman EH, Williams KJ, 
Tabas I. Acid sphingomyelinase promotes lipoprotein retention within 
early atheromata and accelerates lesion progression. Arterioscler Thromb 
Vasc Biol. 2008;28:1723–1730.
 33. Vasile E, Antohe F, Simionescu M, Simionescu N. Transport pathways of 
beta-VLDL by aortic endothelium of normal and hypercholesterolemic 
rabbits. Atherosclerosis. 1989;75:195–210.
 34. Truskey GA, Roberts WL, Herrmann RA, Malinauskas RA. Measurement 
of endothelial permeability to 125I-low density lipoproteins in rabbit 
arteries by use of en face preparations. Circ Res. 1992;71:883–897.
 35. Rozenberg I, Sluka SH, Rohrer L, Hofmann J, Becher B, Akhmedov A, 
Soliz J, Mocharla P, Borén J, Johansen P, Steffel J, Watanabe T, Lüscher 
TF, Tanner FC. Histamine H1 receptor promotes atherosclerotic lesion 
formation by increasing vascular permeability for low-density lipopro-
teins. Arterioscler Thromb Vasc Biol. 2010;30:923–930.
 36. Shao B, Pennathur S, Heinecke JW. Myeloperoxidase targets apolipopro-
tein A-I, the major high density lipoprotein protein, for site-specific oxida-
tion in human atherosclerotic lesions. J Biol Chem. 2012;287:6375–6386.
 37. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung 
MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell 
J, Geary R, Chait A, Zhao XQ, Elkon K, Marcovina S, Ridker P, Oram 
JF, Heinecke JW. Shotgun proteomics implicates protease inhibition and 
complement activation in the antiinflammatory properties of HDL. J Clin 
Invest. 2007;117:746–756.
 38. Davidson WS, Silva RA, Chantepie S, Lagor WR, Chapman MJ, Kontush 
A. Proteomic analysis of defined HDL subpopulations reveals particle-
specific protein clusters: relevance to antioxidative function. Arterioscler 
Thromb Vasc Biol. 2009;29:870–876.
 39. Holzer M, Wolf P, Curcic S, Birner-Gruenberger R, Weger W, Inzinger M, 
El-Gamal D, Wadsack C, Heinemann A, Marsche G. Psoriasis alters HDL 
composition and cholesterol efflux capacity. J Lipid Res. 2012;53:1618–1624.
 40. Tölle M, Huang T, Schuchardt M, Jankowski V, Prüfer N, Jankowski J, 
Tietge UJ, Zidek W, van der Giet M. High-density lipoprotein loses its 
anti-inflammatory capacity by accumulation of pro-inflammatory-serum 
amyloid A. Cardiovasc Res. 2012;94:154–162.
 41. Riwanto M, Rohrer L, Roschitzki B, Besler C, Mocharla P, Mueller 
M, Perisa D, Heinrich K, Altwegg L, von Eckardstein A, Lüscher TF, 
Landmesser U. Altered activation of endothelial anti- and proapop-
totic pathways by high-density lipoprotein from patients with coronary 
artery disease: role of high-density lipoprotein-proteome remodeling. 
Circulation. 2013;127:891–904.
 42. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology 
for the Investigation of the Treatment Effects of Reducing Cholesterol 
(ARBITER) 2: a double-blind, placebo-controlled study of extended-
release niacin on atherosclerosis progression in secondary prevention 
patients treated with statins. Circulation. 2004;110:3512–3517.
 43. Vogt A, Kassner U, Hostalek U, Peiter A, Steinhagen-Thiessen E. Safety 
and tolerability of nicotinic acid: results of the multicenter, open, prospec-
tive NAUTILUS study [in German]. MMW Fortschr Med. 2006;148:41.
 44. Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend 
D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman 
BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees 
and Investigators. Rationale and design of the dal-OUTCOMES trial: 
efficacy and safety of dalcetrapib in patients with recent acute coronary 
syndrome. Am Heart J. 2009;158:896–901.e3.
 45. McKenney J, Bays H, Koren M, Ballantyne CM, Paolini JF, Mitchel Y, 
Betteridge A, Kuznetsova O, Sapre A, Sisk CM, Maccubbin D. Safety of 
extended-release niacin/laropiprant in patients with dyslipidemia. J Clin 
Lipidol. 2010;4:105–112.e1.
 46. Nicholls SJ. Is niacin ineffective? Or did AIM-HIGH miss its target? Cleve 
Clin J Med. 2012;79:38–43.
 47. Rader DJ, Tall AR. The not-so-simple HDL story: is it time to revise the 
HDL cholesterol hypothesis? Nat Med. 2012;18:1344–1346.
1654
 48. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF,
Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL,
Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity,
high-density lipoprotein function, and atherosclerosis. N Engl J Med. 
2011;364:127–135.
 49. Li XM, Tang WH, Mosior MK, Huang Y, Wu Y, Matter W, Gao V, Schmitt 
D, Didonato JA, Fisher EA, Smith JD, Hazen SL. Paradoxical association 
of enhanced cholesterol efflux with increased incident cardiovascular 
risks. Arterioscler Thromb Vasc Biol. 2013;33:1696–1705.
 50. Macheboeuf M. Recherches sur les phosphoaminolipides et les sterids du 
serum et du plasma sanguins: ii etude physiochimique de la fraction pro-
teidique la plus riche en phospholipids et in sterides: proteidique la plus
riche en phospholipids et in steridesproteidique la plus riche en phospho-
lipids et in sterides. Bull Soc Chim Biol. 1929;11:485–503.
CLINICAL PERSPECTIvE
Much of what is known about apolipoprotein A1 (apoA1) and high-density lipoprotein (HDL) comes from investigations 
using isolated HDL particles from the circulation with the use of buoyant density ultracentrifugation and not from HDL or 
apoA1 directly recovered from the human artery wall. A longstanding assumption is that measurement of circulating HDL 
cholesterol, apoA1, or even cholesterol efflux activity provides insights into biological processes relevant within the artery 
wall. ApoA1 recovered from human atherosclerotic lesions, however, is known to be highly oxidized, and ex vivo oxidation 
of apoA1 or HDL to an extent comparable to that observed in vivo both cross-links apoA1 and inhibits cholesterol efflux and 
lecithin-cholesterol acyltransferase activities of the lipoprotein. Herein we directly examined the function and distribution 
of apoA1 recovered from normal and atherosclerotic plaque-laden human aorta. Remarkably, the distribution and function 
of apoA1 in the artery wall were markedly distinct from those observed within the circulation. First, apoA1 was 100-fold 
enriched within atherosclerotic plaque compared with normal arterial tissue. Furthermore, arterial wall apoA1 was predomi-
nantly lipid-poor, not associated with HDL, extensively oxidatively cross-linked, and functionally impaired with respect to 
both cholesterol efflux and lecithin-cholesterol acyltransferase activities. Collectively, these findings argue that circulating 
levels of HDL cholesterol, HDL particles, or apoA1 inadequately reflect apoA1 biology within the artery wall. Instead, our 
findings suggest that examination of circulating lipid-poor apoA1 forms or detection of structurally specific oxidatively 
modified forms of apoA1 may better reflect processes important within the vessel wall and for rendering HDL dysfunctional.
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